Withdrawal of Inhaled Corticosteroids from Patients with COPD; Effect on Exacerbation Frequency and Lung Function: A Systematic Review
Open Access
- 1 June 2024
- journal article
- review article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 19, 1403-1419
Abstract
Background: Inhaled corticosteroid (ICS) therapy has been demonstrated to reduce the risk of COPD exacerbations. It should only be prescribed to COPD patients who are not adequately controlled by dual long-acting bronchodilator therapy and who have ≥ 2 exacerbations per year and a blood eosinophil count ≥ 300cells/μL. ICS therapy is widely prescribed outside guidelines to COPD patients, making ICS withdrawal an important consideration. This systematic review aims to provide an up-to-date analysis of the effect of ICS withdrawal on exacerbation frequency, change in lung function (FEV1) and to determine the proportion of COPD patients who resume ICS therapy following withdrawal. Methods: Randomised controlled trials (RCTs) and observational studies which compared ICS withdrawal with ICS continuation treatment were included. Cochrane Central, Web of Science, CINHAL, Embase and OVID Medline were searched. Risk of bias was assessed using the Cochrane RoB2 tool and the Newcastle-Ottawa Scale. Quality assessment of RCTs was conducted using GRADE. Meta-analysis of post-hoc analyses of RCTs of ICS withdrawal, stratified by blood eosinophil count (BEC), was undertaken. Results: Ten RCTs (6642 patients randomised) and 6 observational studies (160,029 patients) were included in the results. When ICS was withdrawn and long-acting bronchodilator therapy was maintained, there was no consistent difference in exacerbation frequency or lung function change between the ICS withdrawal and continuation trial arms. The evidence for these effects was of moderate quality. There was insufficient evidence to draw a firm conclusion on the proportion of patients who resumed ICS therapy following withdrawal (estimated range 12– 93% of the participants). Discussion: Withdrawal of ICS therapy from patients with COPD is safe and feasible but should be accompanied by maintenance of bronchodilation therapy for optimal outcomes.Keywords
This publication has 36 references indexed in Scilit:
- A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patientsnpj Primary Care Respiratory Medicine, 2022
- Goals of COPD treatment: Focus on symptoms and exacerbationsRespiratory Medicine, 2020
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non‐frequently exacerbating COPD patients: The FLASH randomized controlled trialRespirology, 2018
- Withdrawal of inhaled corticosteroids in COPD: A meta-analysisPulmonary Pharmacology & Therapeutics, 2017
- Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalnpj Primary Care Respiratory Medicine, 2016
- Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialThe Lancet Respiratory Medicine, 2016
- Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPDNew England Journal of Medicine, 2014
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- COPD exacerbations: defining their cause and preventionThe Lancet, 2007